SAN DIEGO--15 Jul--PRNewswire-AsiaNet/InfoQuest
With the recent FDA approval of the new P2Y12 inhibitor, prasugrel (Effient), Accumetrics, Inc. announces that its VerifyNow P2Y12 Test is not only able to assess response to Plavix(R), but also its newly approved competitor, Effient. In obtaining a result from the VerifyNow System, physicians are provided objective information to determine the response of an individual patient to their antiplatelet therapy, regardless of the P2Y12 inhibitor that is prescribed.
"We are very excited with our product position and timing with the release of this therapeutic alternative to Plavix," said Timothy I. Still, President and CEO of Accumetrics. "We feel the VerifyNow System can dramatically contribute to a physician's ability to enhance care for patients undergoing percutaneous coronary intervention and receiving the antiplatelet therapy that follows. In having this alternative therapy, physicians can now utilize the results of the VerifyNow System to assist in the selection of the therapy that
Accumetrics' VerifyNow P2Y12 Test is used to measure the level of P2Y12 receptor blockade and has been in used globally to assess a patient's response to both clopidogrel and prasugrel in clinical trials as well as in clinical practice within the hospital and physician office settings.
About Accumetrics (www.accumetrics.com)
Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.
Accumetrics' VerifyNow System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents.
Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient) and clopidogrel (Plavix)), and the GP IIb/IIIa inhibitors (e.g. ReoPro(R) and Integrilin(R)), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.
The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis. Effient is a registered trademark of Lilly-Daiichi Sankyo.
CONTACT:
Jules Abraham
Lippert/Heilshorn & Associates
212-838-3777
Timothy I. Still
President and CEO
Accumetrics
858-404-8260
SOURCE: Accumetrics
CONTACT: Jules Abraham of Lippert/Heilshorn & Associates, +1-212-838-3777,
--Distributed by AsiaNet ( www.asianetnews.net )--
การทดสอบการทำงานของเกล็ดเลือดอาจมีส่วนช่วยในการตัดสินใจรักษาผู้ป่วย แอคคิวเมตริกส์ อิงค์ (Accumetrics, Inc.) ผู้พัฒนา VerifyNow System ซึ่งเป็นระบบวัดการตอบสนองของผู้ป่วยต่อยาต้านเกล็ดเลือดหลากหลายชนิดที่ใช้ง่ายและวัดผลได้อย่างรวดเร็วตัวแรก ประกาศในวันนี้ว่า ข้อเสนอแนะใหม่ว่าด้วยการทดสอบปฏิกิริยาตอบสนองของเกล็ดเลือด (platelet reactivity testing) ถูกรวมเข้าเป็นส่วนหนึ่งในแนวทางปฏิบัติ 2011 ACCF/AHA Guidelines สำหรับรักษาผู้ป่วยกลุ่ม UA/NSTEMI ข้อเสนอแนะดังกล่าวซึ่งได้รับการเผยแพร่ในวารสาร Journal